Scolyer, Richard

Dataset for the Reporting of Merkel Cell Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

Abstract Accurate and complete pathology reports are critical for the optimal management of cancer patients. Protocols for the pathologic reporting of Merkel cell carcinoma (MCC) have been developed independently by the Royal College of Pathologists (UK) and the College of American Pathologists. In this study, data elements for pathologic reporting of MCC were analyzed by an international panel of pathologists and clinicians with the aim of developing a common, internationally agreed upon dataset useful for clinical practice. The International Collaboration on Cancer Reporting expert review panel developed a protocol containing "core" (required) and "noncore" (recommended) elements. Core elements were [...]

November 1st, 2022|Comments Off on Dataset for the Reporting of Merkel Cell Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

Clinical Management of Melanocytic Tumours of Uncertain Malignant Potential (MelTUMPs), including Melanocytomas: A Systematic Review and Meta-Analysis.

Abstract Little guidance is currently available for managing patients with melanocytic tumours of uncertain or low malignant potential (MelTUMPs, including melanocytomas), in particular the optimal excision margins and whether to offer sentinel node biopsy (SNB). The objective of this review was to evaluate excision margins and the prognostic utility of SNB by systematic review of the literature and meta-analysis. PRISMA guidelines were followed. Medline, EMBASE and Cochrane databases were searched to October 2021 for studies of patients with MelTUMPs reporting excision margins and/or SNB-positivity. Meta-analysis was performed on the SNB-positivity rate using a random effects model, followed by sensitivity [...]

October 17th, 2022|Comments Off on Clinical Management of Melanocytic Tumours of Uncertain Malignant Potential (MelTUMPs), including Melanocytomas: A Systematic Review and Meta-Analysis.

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.

Abstract Aneuploidy, the state of the cell in which the number of whole chromosomes or chromosome arms becomes imbalanced, has been recognized as playing a pivotal role in tumor evolution for over 100 years. In melanoma, the extent of aneuploidy, as well as the chromosomal regions that are affected differ across subtypes, indicative of distinct drivers of disease. Multiple studies have suggested a role for aneuploidy in diagnosis and prognosis of melanomas, as well as in the context of immunotherapy response. A number of key constituents of the cell cycle have been implicated in aneuploidy acquisition in melanoma, including [...]

October 6th, 2022|Comments Off on Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.

Metastasizing and non-metastasizing thick melanoma: clinicopathological predictors and molecular profiling.

Abstract Background. Cutaneous melanoma (CM) is the most aggressive form of skin cancer and its worldwide incidence rises faster than that of any other cancer (1). Early stages can successfully be treated by surgery, but once metastasis has occurred, the prognosis is infaust. Prognosis can be predicted on the basis of the stage of the patient and depends on a number of clinicopathological parameters, including thickness and ulceration of the primary melanoma (2). However, some 5-10% of thick (≥2mm) melanomas do not follow this scenario and run an unpredictable course. In our earlier study on thick primary melanomas (≥2mm) [...]

October 1st, 2022|Comments Off on Metastasizing and non-metastasizing thick melanoma: clinicopathological predictors and molecular profiling.

Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework.

Abstract Background: Sentinel node biopsy (SN biopsy) is a surgical procedure used to accurately stage patients with primary melanoma at high risk of recurrence. Although Australian Melanoma Management Guidelines recommend SN biopsy be considered in patients with melanomas > 1 mm thick, SN biopsy rates in Australia are reportedly low. Our objective was to identify factors impacting the acceptance, adoption and adherence to the Australian SN biopsy guideline recommendations. Methods: Opinions of Australian key informants including clinicians, representatives from melanoma education and training providers, professional associations and colleges, and melanoma advocacy organisations were collected through semi-structured interviews (n = [...]

October 1st, 2022|Comments Off on Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework.

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.

Abstract Aneuploidy, the state of the cell in which the number of whole chromosomes or chromosome arms becomes imbalanced, has been recognized as playing a pivotal role in tumor evolution for over 100 years. In melanoma, the extent of aneuploidy, as well as the chromosomal regions that are affected differ across subtypes, indicative of distinct drivers of disease. Multiple studies have suggested a role for aneuploidy in diagnosis and prognosis of melanomas, as well as in the context of immunotherapy response. A number of key constituents of the cell cycle have been implicated in aneuploidy acquisition in melanoma, including [...]

October 1st, 2022|Comments Off on Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.

Obesity is associated with altered tumor metabolism in metastatic melanoma.

Abstract Purpose: Overweight/obese (OW/OB) patients with metastatic melanoma unexpectedly have improved outcomes with immune checkpoint inhibitors (ICI) and BRAF-targeted therapies. The mechanism(s) underlying this association remain unclear, thus we assessed the integrated molecular, metabolic, and immune profile of tumors, as well as gut microbiome features, for associations with patient body mass index (BMI). Experimental Design: Associations between BMI [normal (NL < 25) or OW/OB (BMI ≥ 25)] and tumor or microbiome characteristics were examined in specimens from 782 patients with metastatic melanoma across 7 cohorts. DNA associations were evaluated in The Cancer Genome Atlas cohort. RNA sequencing from 4 [...]

September 27th, 2022|Comments Off on Obesity is associated with altered tumor metabolism in metastatic melanoma.

Hypoxia controls the glycome signature and galectin-8 – ligand axis to promote pro-tumorigenic properties of metastatic melanoma.

Abstract The prognosis for patients with metastatic melanoma (MM) involving distant organs is grim, and treatment resistance is potentiated by tumor-initiating cells (TIC) that thrive under hypoxia. MM cells, including TICs, express a unique glycome featuring i-linear poly-N-acetyllactosamines (poly-LacNAc) via loss of I-branching enzyme, β1,6 N-acetylglucosaminyltransferase 2 (GCNT2). Whether hypoxia instructs MM TIC development by modulating the glycome signature remains unknown. Here, we explored hypoxia-dependent alterations in MM glycome-associated genes and found that GCNT2 was downregulated and a galectin (Gal)-8 – ligand axis, involving both extracellular and cell-intrinsic Gal-8, was induced. Low GCNT2 levels correlated with poor patient outcome [...]

September 26th, 2022|Comments Off on Hypoxia controls the glycome signature and galectin-8 – ligand axis to promote pro-tumorigenic properties of metastatic melanoma.

Comparative genomics provides etiological and biological insights into melanoma subtypes

Abstract Background: Metastasectomy for selected patients with melanoma was associated with improved survival in the era before effective systemic therapy. Emerging evidence shows that these benefits persist even in this era of BRAF-targeted therapy and immune checkpoint inhibitor immunotherapy. This study aimed to evaluate the outcomes of salvage metastasectomy after failure of systemic therapy. Methods: Stage 3 or 4 melanoma patients with extracranial disease progression after at least 4 weeks of systemic treatment between 2009 and 2020 were identified and categorized as resected to no evidence of disease (NED), non-progressive residual disease (NPRD), or progressive residual disease (PRD). Systemic [...]

September 13th, 2022|Comments Off on Comparative genomics provides etiological and biological insights into melanoma subtypes
Go to Top